Nutrient infusion preparation

Abstract: A nutrient infusion preparation comprises a solution containing a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and a solution containing electrolytes and amino acids. Also the nutrient infusion preparation comprises a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and a solution (B) containing electrolytes and/or amino acids. A container having a plurality of chambers which are isolated from each other by partitions capable of being easily opened, whose respective chambers contain the fat emulsion (A) and said solution (B) and optionally a solution (C) containing saccharides. The infusion preparation of the present invention supplies various nutrient components including fatty acids required biologically to patients and enables amelioration or prevention of essential fatty acid deficiencies during TPN therapy. Further, the infusion preparation enables visual identification of insoluble foreign bodies present in an infusion container and can be administered to patients through a sterilization filter.

Description: Field of the Invention The present invention relates to an integrated nutrient infusion preparation for total parenteral nutrition (TPN) therapy. By the infusion preparation according to the present invention, an essential fatty acid deficiency can be ameliorated or prevented while supplementing various nutritional components that are biologically required. In addition, an appreciable transparency of the nutrient infusion preparation enables a visual identification of insoluble foreign bodies present in an infusion container as well as administration through a sterilization filter to a patient, whereby a marked advantage is exerted. Background of the Invention A method for supplementing nutrition to a patient who is hospitalized due to a disease or injury has been conventionally an oral administration, which is the most natural and desirable method. However, to a patient for whom it is completely impossible to take nutrition orally for a prolonged period, a TNP solution containing various nutritional components such as saccharides, electrolytes and amino acids is administered generally via the central vein of the patient. A TPN solution is administered to a patient usually after mixing saccharides, electrolytes and amino acids with each other to obtain the infusion preparation aseptically in a pharmaceutical laboratory in a hospital. Since this mixing procedure for obtaining the infusion preparation is complicated, the infusion preparation is contained in a multi-chamber container in which saccharides, electrolytes and amino acids have previously been filled but the saccharides and the amino acids have been separately filled because of their interaction. The multi-chamber container such as plastic containers having a plurality of chambers have already been developed and marketed for the purpose of saving the effort in the complicated procedure described above as well as preventing an invasion of microorganisms during the mixing procedure. However, a patient who is administered with only a TPN solution containing various nutritional components such as saccharides, electrolytes and amino acids for a prolonged period will exhibit the symptoms of an essential fatty acid deficiency such as scale efflorescence, eczematoid eruption, retarded wound healing, thrombocytopenia, fat swelling, anemia, susceptibility to infection, increased water intake without increasing urine volume, growth disturbance, impotenia generandi and the like, which are problematic during TPN therapy. In addition, an essential fatty acid deficiency which is rare in a human living a routine life is observed frequently in a patient receiving only transvenous nutrition, and is developed within a period of 4 to 6 weeks especially when an energy source is only saccharides. Such essential fatty acid deficiency can be avoided by administering an essential fatty acid-rich fat emulsion concomitantly during TPN therapy. It has been believed that the essential fatty acid deficiency can be prevented or ameliorated by daily administration of 50 to 100 mL of a 10 % fat emulsion. In clinical practice, 200 to 500 mL of a 10% or 20% fat emulsion are given 2 or 3 times a week (Mascioli et al., Eur. J.Clin. Nutr, 51, 232-242 (1997), Tsukamoto et al., JJPEN, 14, (2) 135-138 (1992), Saito et al., JJPEN, 14 (2), 143(1992), Hiramatsu et al., NIPPON RINSHO, 49 (special edition), 125-129 (1991), Yoshimoto et al., Medical Practice, 7, 114-122 (1990), A.Tashiro, PEN, 15 (2), 19-21 (1997)). US 5 674 527 discloses a nutrient infusion preparation comprising a sugar, amino acids, electrolytes and a fat emulsion, wherein said fat emulsion has a mean particle size of 0.17 µm or less. In a method for administering a fat emulsion during TPN therapy, a TPN solution is mixed directly with a fat emulsion, or a fat emulsion is introduced via a TPN infusion line, or it is injected separately via the peripheral vein. While the essential fatty acid deficiency can be prevented by combining a TPN solution with a fat emulsion as discussed above, mixing of the fat emulsion with the electrolytes infusion causes an aggregation of fat particles due to the presence of divalent cations such as calcium ions or magnesium ions in the electrolytes. And mixing of the fat emulsion with amino acids also causes an aggregation of the fat particles due to the presence of basic amino acids such as arginine, lysine or histidine similarly to the above electrolytes. The resultant aggregation of fat, when administered to a living body may cause adverse reactions such as an embolism of a pulmonary capillary vessel. Accordingly, mixing of a TPN solution with a fat emulsion should be carried out carefully, for example, by ensuring consumption within 24 hours. A commercially available fat emulsion is opaque like milk. As a result, a high TPN solution which is incorporated with the fat emulsion appears opaque even if the amount of the fat emulsion is small. Thus, it is impossible to identify insoluble foreign bodies, if any, in the TPN solution. Accordingly, the United State Food and Drug Administration (FDA) recommended on April 18, 1994 that a fat emulsion should be given by a different route entirely from that for an infusion preparation containing saccharides, electrolytes and amino acids. A TPN solution is administered to a patient generally after filtration through a sterilization filter having a pore size of 0.2 to 0.45 µm in order to prevent contamination with microorganisms. However, it is difficult to filter the fat emulsion to be incorporated in the TPN solution through a sterilization filter having a pore size of 0.2 to 0.45 µm, since it contains fat particles having a mean particle size usually of about 0.200 to 0.300 µm together with rough particles having a size as large as 1.000 µm or greater. Accordingly, there is no option practically but to use a filter having a pore size of 1.2 µm which can filter the fat emulsion before administration in order to remove aggregated fat particles, foreign bodies and large-sized microorganisms such as Candida albicans species. Because of the above described reasons, it has been difficult to provide a TPN solution containing fat as a single-component product, in spite of the fact that administration of the fat emulsion is effective in preventing an essential fatty acid deficiency during TPN therapy. Summary of the Invention In the course of formulating a TPN solution containing a fat emulsion, we discovered, based on the fact that it is necessary to store the fat emulsion, electrolytes and amino acids separately until just before use, that the problems discussed above can be solved by storing the fat emulsion, the electrolytes and the amino acids separately in a plurality of chambers in a flexible plastic container and by using a fat emulsion consisting essentially of fat particles whose mean particle size is smaller than that of a conventional fat emulsion, thus establishing the present invention. Thus, one embodiment of the present invention is a nutrient infusion preparation comprising a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and a solution containing electrolytes and/or amino acids. The former emulsion is separated from the latter solution and the emulsion and the solution are mixed with each other just before administration to a patient. Also, another embodiment of the present invention is a nutrient infusion preparation comprising a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and solution (B) containing electrolytes and amino acids. Furthermore, another embodiment of the present invention is a nutrient infusion preparation comprising a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, a solution (B-1) containing electrolytes and a solution (B-2) containing amino acids. Another embodiment of the present invention is a container for a nutrient infusion preparation which is characterized by having a plurality of chambers isolated from each other by partitions capable of being easily opened, wherein one chamber contains a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and the other chamber contains a solution containing electrolytes and/or amino acids. Furthermore, another embodiment of the present invention is a container for a nutrient infusion preparation having a plurality of chambers which are isolated from each other by partitions capable of being easily opened, wherein one chamber contains a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and the other chamber contains a solution (B) containing electrolytes and amino acids. Furthermore, a further embodiment of the present invention is a container for a nutrient infusion preparation which is characterized by having a plurality of chambers isolated from each other by partitions capable of being easily opened, wherein one chamber contains a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and the other chambers respectively contain a solution (B-1) containing electrolytes and a solution (B-2) containing amino acids. The present invention also provides a method for producing a fat emulsion comprising coarsely emulsifying a fat using a high speed agitating homogenizer in the presence of saccharides and/or polyhydric sugar alcohols, adding water for injection and finely emulsifying the resultant coarse emulsion using a high pressure spray homogenizer under a pressure of 2000 to 313810 kPa (3200 kgf/cm 2 ) with a pass number through homozenizer of 5 to 20 to obtain a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium. Brief Description of the Drawings Figure 1 is a planar view of an infusion container consisting of two chambers containing an inventive infusion preparation. Figure 2 is a planar view of an infusion container consisting of three chambers containing an inventive infusion preparation. Description of Preferred Embodiments A fat emulsion (A) used in the present invention consists essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium. Such fat emulsion is a fat emulsion for a nutrition supplement obtained by emulsifying fat and if necessary, saccharides and/or polyhydric sugar alcohols using an emulsifier. Fat includes vegetable oils, fish oils, and triglycerides of middle-chain fatty acids or chemically synthesized triglycerides. Those exemplified typically comprise vegetable oils such as soybean oil, safflower oil, olive oil, cottonseed oil, corn oil, palm oil, beefsteak plant oil and sesame oil, as well as fish oils, and synthesized triglycerides of middle- or long-chain fatty acids. Two or more of these materials can also be used in combination. The concentration of the fat in solution (A) is 0.15 to 15.0 g/dL. An emulsifier used in the present invention is egg yolk phospholipid, hydrogenated egg yolk phospholipid, soybean phospholipid, hydrogenated soybean phospholipid or a nonionic surfactant. Those exemplified typically comprise a purified egg yolk lecithin, a purified soybean lecithin and hydrogenated derivatives thereof, nonionic surfactants such as Polysorbate 80 and HCO-60 (trade names) and the like. Two or more of these emulsifiers can also be used in combination. The amount of the emulsifier in the present invention is 0.1 to 0.5 part by weight, preferably 0.3 to 0.5 part by weight, per 1 part by weight of fat. A saccharide used in the present invention can be any of those used customarily in various infusion preparations such as monosaccharides such as glucose and fructose, and disaccharides such as maltose. Among these, a reducing sugar such as glucose, fructose and maltose is particularly preferred. A polyhydric sugar alcohol used in the present invention can be, for example xylitol, sorbitol, mannitol and the like. Two or more of these saccharides and polyhydric sugar alcohols can also be used in combination. The concentration of the saccharides or the polyhydric sugar alcohols in solution (A) is 2.5 to 60 g/dL. Fat emulsion (A) can be, for example prepared by emulsifying fat in the presence of saccharides and/or polyhydric alcohols to obtain a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm. A typical procedure involves coarse emulsification of a fat using a high speed agitating homogenizer "POLYTRON"® (KINEMATICA), followed by addition of water for injection, further followed by fine emulsification using a high pressure spray homogenizer "DeBEE" (BEE International) under a pressure of 196130 to 313810 kPa (2000 to 3200 kgf/cm 2 ), for example, 274590 kPa (2800 kgf/cm 2 ), with a pass number through homozenizer of 5 to 30. Subsequently, a resultant fat emulsion is sterilized by an autoclave, hot water immersion or filtration sterilization. The coarse emulsified fat particles have a mean particle size of preferably at least 1 µm, more preferably at least 3 µm. In the present invention, a fat concentration of 0.15 to 15.0 g/dL is sufficient for preventing an essential fatty acid deficiency. At such concentration, by adjusting the amount of an emulsifier to be added, the amounts of saccharides and polyhydric sugar alcohols to be added, the emulsifying pressure and the number of emulsifying cycles so that a mean particle size of the fat particles of 0.003 to 0.100 µm can be obtained, a fat-containing TPN solution exhibiting a satisfactory transparency can be obtained when using either solution (A) alone or after mixing with solution (B), (B-1) or (B-2). In addition, a fat-containing TPN solution of the present invention can advantageously be filtered through a sterilization filter having a pore size of 0.2 µm before administering to a patient. Solution (B), (B-1) or (B-2) used in the present invention contains electrolytes and/or amino acids. Such electrolytes can be, for example a water-soluble salt of inorganic substances such as sodium, potassium, calcium, magnesium, zinc, iron, copper, manganese, iodine, phosphorus and the like; for instance, a chloride, sulfate, acetate, gluconate, lactate, and glycerophosphate. Especially, electrolytes such as salts of sodium, potassium, calcium, magnesium, chloride, phosphate and zinc are preferred. An amino acid used in the present invention is an essential amino acid, a non-essential amino acid and/or salts, esters and N-acyl derivatives thereof. Typically, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, L-glycine and the like are exemplified. These amino acids can be in the forms of inorganic acid salts such as L-arginine hydrochloride, L-cysteine hydrochloride, L-glutamine hydrochloride, L-histidine hydrochloride and L-lysine hydrochloride, organic acid salts such as L-lysine acetate and L-lysine malate, esters such as L-tyrosine methylester, L-methionine methylester and L-methionine ethylester, N-substituted derivatives such as N-acetyl-L-cysteine, N-acetyl-L-tryptophan and N-acetyl-L-proline, and dipeptides such as L-tyrosyl-L-tyrosine, L-alanyl-L-tyrosine, L-arginyl-L-tyrosine and L-tyrosyl-L-arginine. In the present invention, the nutrient infusion has the constituents listed the following table 1. The solution in the present invention is prepared in a standard manner. Component Concentration Fat 1.5 to 100.0 g/L Emulsifier 0.15 to 50.0 g/L Saccharide or polyhydric alcohol 25.0 to 350.0 g/L L-Isoleucine 0.5 to 5.5 g/L L-Leucine 0.5 to 7.0 g/L L-Lysine 0.5 to 7.0 g/L L-Methionine 0.1 to 5.0 g/L L-Phenylalanine 0.1 to 6.0 g/L L-Threonine 0.2 to 3.0 g/L L-Tryptophan 0.1 to 2.0 g/L L-Valine 0.5 to 6.0 g/L L-Alanine 0 to 5.0 g/L L-Arginine 0 to 9.0 g/L L-Aspartic acid 0 to 2.5 g/L L-Cysteine 0 to 0.5 g/L L-Glutamic acid 0 to 3.0 g/L L-Histidine 0 to 3.5 g/L L-Proline 0 to 4.5 g/L L-Serine 0 to 3.0 g/L L-Tyrosine 0 to 0.4 g/L Glycine 0 to 7.0 g/L Sodium 20 to 150 mEq/L Potassium 10 to 50 mEq/L Calcium 0 to 15 mEq/L Magnesium 0 to 15 mEq/L Chloride 20 to 150 mEq/L Phosphate 0 to 15 mEq/L Zinc 0 to 100 µmol/L In the present invention, the fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, or the solutions containing electrolytes and/or amino acids may also contain saccharides or polyhydric sugar alcohols. When a solution containing amino acids contains saccharides, the pH is preferably acidic. The fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium may further contain electrolytes and/or amino acids. The amino acid is preferably a neutral amino acid or an acidic amino acid. In the present invention,a saccharide component in the fat emulsion rarely undergoes an interaction with oil. In addition, an incorporation of saccharide into a fat emulsion allows the refractive index of an oil phase of the fat emulsion to be close to that of a water phase, resulting in a transparent appearance of the fat emulsion. An additional incorporation of glycerin, which is a polyhydric alcohol, serves to ensure further transparency. Storage of saccharides in a chamber different from that for amino acids serves to avoid a Maillard reaction between the two. It has been known that the presence of saccharides and polyhydric alcohols during an emulsifying process of an oil can allow the fat particles to be micronized (United States Patents No. 5,626,880 and 5,674,527). Smaller fat particles in a fat emulsion cause lower scattering of transmitted light, resulting in higher transparency. Nevertheless, a lower limit of a particle size of a conventional fat emulsion was as large as 0.14 µm. On the contrary, the present invention employs a fat emulsion consisting essentially of fat particles whose mean particle size is as small as 0.003 to 0.100 µm, preferably 0.010 to 0.100 µm and a dispersion medium. It is difficult to prepare a fat emulsion consisting essentially of fat particles whose mean particle size is less than 0.003 µm and a dispersion medium, and use of a fat emulsion whose mean particle size is greater than 0.100 µm results in turbidity of 150 degrees or higher even if a large amount of a saccharide and/or a polyhydric sugar alcohol is added. In the present invention, a fat emulsion-containing TPN solution is transparent even after mixing the above mentioned fat emulsion (A) and solution (B) containing electrolytes and amino acids or solution (B-1) containing electrolytes optionally with solution (B-2) containing amino acids, and can be filtered through a filter having a pore size of 0.2 µm. A fat emulsion according to the present invention can be obtained by a coarse emulsification of fat followed by fine emulsification using a high pressure spray homogenizer under a pressure of 196130 to 313810 kPa (2000 to 3200 kgf/cm 2 ) with a pass number through homozenizer of 5 to 30 further followed by sterilization by an autoclave, a hot water immersion or a filtration sterilization. The fat emulsion is stored in a chamber of an infusion container in which a solution containing electrolytes and/or amino acids is also stored. An infusion container according to the present invention has a plurality of chambers, which are isolated from each other with partitions that are designed to be capable of being easily opened. For example, such an infusion container is a flexible plastic container having a plurality of chambers, wherein all or a part of partitions which isolate the chambers from each other can externally be opened to allow the chambers to communicate with each other. One typically exemplified is an infusion bag which is partitioned into 2 or 3 chambers with sealed barriers, which can be opened immediately before use by pushing the outside of the bag by hand (Figures 1 and 2 and as disclosed in Japanese Laid-Open Patent Publication Nos. 8-191873 and 8-182739) . In Figure 1, chambers 1 and 2 for storing an infusion preparation are provided together with barrier 3, preparation inlet 4 and outlet 5. In Figure 2, chambers 1, 2 and 3 each for storing an infusion preparation are provided together with barriers 4 and 5, inlets 6, 7 and 8 and outlet 9. In such infusion container, one chamber can contain (A) containing a fat emulsion consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm, and the other chamber can contain solution (B) containing electrolytes and amino acids. Alternatively, one chamber can contain a fat emulsion (A) consisting essentially of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, and the other chambers can contain solution (B-1) containing electrolytes and solution (B-2) containing amino acids respectively. An infusion container according to the present invention is not limited to one having 2 or 3 chambers and can have 4 or more chambers for further containing a solution (C) containing saccharides, if necessary. In the present invention, turbidity of a mixed solution after mixing emulsion (A), solution (B), (B-1) or (B-2) and, if necessary, solution (C) prepared as described above is usually 20 to 150 degrees, preferably 20 to 130 degrees, which allows the mixed solution to be passed through a sterilization filter whose pore size is 0.2 µm. Accordingly, insoluble foreign bodies in the TPN solution, if any, can readily be identified. In addition, it is possible not only to remove aggregated fat particles and insoluble foreign bodies but also to prevent infections with microorganisms. The present invention is further detailed in the following examples. Example 1 Fat emulsion (A): 3.6 g of a purified soybean oil and 0.36 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 240 g of glucose in an appropriate amount of water for injection. The mixture was subjected to a high speed agitating homogenizer "POLYTRON"® (KINEMATICA) to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 1200 mL in total, which was subjected to a high pressure spray homogenizer "DeBEE" (BEE International) under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0978 µm. Solution (B): Using a composition shown in Table 3, a solution containing amino acids and electrolytes was prepared, and sterilized by an autoclave. The mean particle size and the turbidity of emulsion (A) thus obtained are shown in Table 4. Fat emulsion (A) and solution (B) were combined in a ratio shown in Table 2 to obtain a mixture whose turbidity and filtration characteristics through a sterilization filter having a pore size of 0.2 µm (NIPRO, Filter set FG-20BY, pore size: 0.2 µm) are also shown in Table 4. Mean particle size and turbidity as shown in Table 4 were determined as follows. (1) Mean fat particle size A device for determining a particle size and a particle size distribution, NICOMP model 380ZLS (Particle Sizing System) was used to determine the mean particle size of a fat particle in a fat emulsion by a dynamic laser light scattering method. (2) Transparency of fat emulsion Using a light absorption photometer U-3000 (HITACHI), a turbidity of a fat emulsion was determined using the absorbance of 1 mg/L of kaolin at 660 nm as 1. The compositions of the infusion preparations, fat emulsion (A), solutions (B) and (C) used in Examples 1 to 7 and Comparative Examples 1 to 3 are shown in Table 2. The numeric data are concentrations of respective solutions. The compositions of solutions (B) in the Examples and Comparative Examples are identical to each other. The composition is shown in Table 3. Component Unit L-Isoleucine g/L 1.0 L-Leucine g/L 1.0 L-Lysine acetate g/L 1.05 L-Methionine g/L 0.5 L-Phenylalanine g/L 0.75 L-Threonine g/L 0.75 L-Tryptophan g/L 0.25 L-Valine g/L 1.0 L-Alanine g/L 0.75 L-Arginine g/L 1.0 L-Aspartic acid g/L 0.1 L-Cysteine g/L 0.1 L-Glutamic acid g/L 0.1 L-Histidine g/L 0.5 L-Proline g/L 0.5 L-Serine g/L 0.15 L-Tyrosine g/L 0.05 Glycine g/L 0.75 Sodium chloride g/L 1.71 Potassium chloride g/L 1.31 Potassium glycerophosphate g/L 7.89 Magnesium sulfate g/L 2.18 Calcium gluconate g/L 3.16 Sodium acetate anhydride g/L 6.03 Zinc sulfate g/L 0.0084 Example 2 Fat emulsion (A): 3.6 g of a purified soybean oil and 1.8 g of a purified egg yolk lecithin were mixed uniformly and combined with an appropriate amount of water for injection, and then subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 1200 mL in total, which was subjected to a high pressure spray homogenizer "DeBEE" under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0519 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. Solution (C): 180 g of glucose was dissolved in an appropriate volume of water for injection to make 360 mL in total. The glucose solution thus obtained was sterilized by an autoclave. The mean particle size and the turbidity of fat emulsion (A) determined in same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A), solutions (B) and (C), which were combined in a ratio, as shown in Table 2 are also shown in Table 4. Example 3 Fat emulsion (A): 5 g of a purified soybean oil and 1.25 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 150 g of glucose in an appropriate amount of water for injection. The mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0585 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A) and solution (B) which were combined in a ratio as shown in Table 2 are also shown in Table 4. Example 4 Fat emulsion (A): 5 g of a purified soybean oil and 2.5 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 150 g of glucose in an appropriate amount of water for injection. The mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0386 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A) and solution (B) which were combined in a ratio as shown in Table 2 are also shown in Table 4. Reference Example 5 Fat emulsion (A): 5.0 g of a purified soybean oil and 2.5 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 25 g of concentrated glycerin and 150 g of glucose in an appropriate amount of water for injection. The mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with a water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0265 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. The mean particle size and the turbidity of fat emulsion (A) determined in a manner similar to that in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A) and solution (B) which were combined in a ratio as shown in Table 2 are also shown in Table 4. Example 6 Fat emulsion (A): 75 g of a purified soybean oil and 37.5 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 300 g of glucose in an appropriate amount of water for injection, and the solution was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0505 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. Solution (C): 180 g of glucose was dissolved in an appropriate volume of water for injection to make 600 mL in total. The glucose solution thus obtained was sterilized by an auoclave. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A), solutions (B) and (C), which were combined in a ratio, as shown in Table 2 are also shown in Table 4. Example 7 Fat emulsion (A): 4.5 g of a purified soybean oil and 2.25 g of a purified egg yolk lecithin were dissolved together with 90 g of glucose in an appropriate amount of water for injection, and the mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 900 mL in total, which was subjected to a high pressure spray homogenizer DeBEE (BEE International) under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, whereby a fine emulsification was effected. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0502 µm. Solution (B): Using a composition as shown in Table 3, a solution containing amino acids and electrolytes was prepared, and sterilized by an autoclave. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A) and solution (B) which were combined in a ratio as shown in Table 2 are also shown in Table 4. Comparative Example 1 Fat emulsion (A): 5 g of a purified soybean oil and 2.5 g of a purified egg yolk lecithin were mixed uniformly and combined with an appropriate amount of water for injection, and the mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, whereby a fine emulsification was effected. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0520 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. Solution (C): 180 g of glucose was dissolved in an appropriate volume of water for injection to make 600 mL in total. The glucose solution thus obtained was sterilized by an atutoclave. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A), solutions (B) and (C), which were combined in a ratio as shown in Table 2 are also shown in Table 4. The turbidity of fat emulsion (A) was 150 or higher, and the turbidity after mixing was also 150 or higher. Comparative Example 2 Fat emulsion (A): 100 g of a purified soybean oil and 50 g of a purified egg yolk lecithin were mixed uniformly and dissolved together with 250 g of glucose in an appropriate amount of a water for injection, and the mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 274590 kPa (2800 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.0777 µm. Solution (B): solution (B) prepared by the same method as that of Example 1. Solution (C): 180 g of glucose was dissolved in an appropriate volume of water for injection to make 600 mL in total. The glucose solution thus obtained was sterilized by an autoclave. The mean particle size and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A), solutions (B) and (C), which were combined in a ratio, as shown in Table 2 are also shown. The turbidity of fat emulsion (A) could not be determined, and the turbidity after mixing could also not be determined. Comparative Example 3 Fat emulsion (A): 5.0 g of a purified soybean oil and 2.5 g of a purified egg yolk lecithin were mixed uniformly and combined with 25 g of concentrated glycerin and 150 g of glucose dissolved in an appropriate amount of water for injection, and the mixture was subjected to a high speed agitating homogenizer to obtain a coarse emulsion. The coarse emulsion thus obtained was combined with water for injection to make 500 mL in total, which was subjected to a high pressure spray homogenizer DeBEE under a pressure of 73550 kPa (750 kgf/cm 2 ) with a pass number through homozenizer of 25, thereby effecting a fine emulsification. The fat emulsion thus obtained was sterilized by an autoclave. The mean particle size obtained was 0.1731 µm. Solution (B): solution (B) prepared by the same method sa that of Example 1. The mean particle and the turbidity of fat emulsion (A) determined in the same manner as in Example 1 are shown in Table 4. The turbidity and the filtration characteristics through a sterilization filter having a pore size of 0.2 µm of fat emulsion (A) and solution (B) which were combined in a ratio as shown in Table 2 are also shown in Table 4. The turbidity of fat emulsion (A) could also not be determined, and the turbidity after mixing could not be determined. Determination item Mean particle size of Fat emulsion (A) Turbidity of fat emulsion (A) Turbidity after mixing Filtration characteristics through 0.20µm filter Unit µm Degree Degree Example 1 0.0979 121.3 100.5 passed Example 2 0.0519 60.08 51.58 passed Example 3 0.0585 88.47 75.20 passed Example 4 0.0386 68.64 55.03 passed reference Example 5 0.0265 32.36 26.41 passed Example 6 0.0505 107.95 122.77 passed Example 7 0.0502 135.03 126.49 passed Comparative Example 1 0.052 150 degree or higher 150 degree or higher - Comparative Example 2 0.0777 Could not detected Could not detected - Comparative Example 3 0.1731 Could not detected Could not detected - As evident from Table 4, the turbidity was 150 degrees or higher when no saccharide or no polyhydric alcohol was contained even if the concentration of the fat in fat emulsion (A) was 1.0 g/dL (Comparative Example 1). The emulsion became turbid when the concentration of fat was high even if a large amount of a saccharide and polyhydric alcohol (Comparative Example 2) were contained. The emulsion became turbid also when the mean particle size became far larger than 0.100 µm even if the composition was quite the same as that of Reference Example 5 (Comparative Example 3). An inventive nutrient infusion preparation gave a turbidity of fat emulsion (A) of 30 to 150 and a turbidity of solution (B) optionally mixed with solution (C) of 20 to 150, exhibiting an excellent transparency, which was due to a mean particle size of 0.003 to 0.100 µm. Example 8 Fat emulsion (A) and solution (B) prepared in Example 1 were contained individually in the two chambers in an infusion container as shown in Figure 1. Just before use, the barriers were opened by an external force to mix the contents with each other, and the mixed solution was allowed to pass through a sterilization filter having a pore size of 0.20 µm. An infusion preparation according to the present invention contains the essential components in a conventional TPN solution such as saccharides, electrolytes and amino acids together with fats, thereby providing a remedy and prevention of an essential fatty acid deficiency which is a side effect during TPN therapy. It also enables administration to a patient after filtration through a sterilization filter having a pore size of 0.20 µm or less, because of which it is possible not only to remove aggregated fat particles and insoluble foreign bodies but also to prevent infections with a microorganisms. In addition, an appreciable transparency of fat emulsion (A) enables a visual identification of an insoluble foreign bodies present in an infusion container. A high transparency of fat emulsion (A) and solution (B), (B-1) or (B-2) optionally mixed with solution (C) makes the preparation familiar and tolerable to a patient. Such advantage is not limited to TPN therapy, and can also be achieved even if the nutrition is supplied via a peripheral vein provided that an appropriate composition of the preparation is selected.

Claims: A transparent nutrient infusion preparation comprising a fat emulsion (A) consisting of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium, wherein the fat emulsion contains 0.15 to 15.0 g/dL of fat, 2.5 to 60 g/dL of a saccharide and/or a polyhydric sugar alcohol, and an emulsifier selected from the group consisting of egg yolk phospholipid, hydrogenated egg yolk phospholipid, soybean phospholipid and hydrogenated soybean phospholipid, obtained by finely emulsifying a coarse emulsion of fat using a high pressure spray homogenizer under a pressure of 196130 to 313810 kPa (2000 to 3200 kgf/cm 2 ) with a pass number through said homogenizer of 5 to 30 and a solution (B) containing electrolytes and/or amino acids. The nutrient infusion preparation of claim 1 wherein the solution containing electrolytes and the solution containing amino acids are separate solutions. The nutrient infusion preparation according to any of claims 1 or 2 wherein said solution containing a fat emulsion further contains electrolytes and/or amino acids. A nutrient infusion preparation according to any of claims 1 or 2 wherein said fat emulsion consisting of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium is a fat emulsion for supplementing nutrition which is obtained by emulsifying a fat in water using an emulsifier in the presence of a saccharide and/or a polyhydric alcohol. A nutrient infusion preparation according to any of claims 1 or 2 wherein said fat emulsion consisting of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium is a fat emulsion for supplementing nutrition which is obtained by emulsifying a fat in water using an emulsifier, and wherein 0.1 to 0.5 part by weight of said emulsifier is incorporated per 1 part by weight of fat. A nutrient infusion preparation according to any of claims 1 or 2 having the constituents listed in the following table: Component Concentration Fat 1.5 to 100.0 g/L Emulsifier 0.15 to 50.0 g/L Saccharide or polyhydric alcohol 25.0 to 350.0 g/L L-Isoleucine 0.5 to 5.5 g/L L-Leucine 0.5 to 7.0 g/L L-Lysine 0.5 to 7.0 g/L L-Methionine 0.1 to 5.0 g/L L-Phenylalanine 0.1 to 6.0 g/L L-Threonine 0.2 to 3.0 g/L L-Tryptophan 0.1 to 2.0 g/L L-Valine 0.5 to 6.0 g/L L-Alanine 0 to 5.0 g/L L-Arginine 0 to 9.0 g/L L-Aspartic acid 0 to 2.5 g/L L-Cysteine 0 to 0.5 g/L L-Glutamic acid 0 to 3.0 g/L L-Histidine 0 to 3.5 g/L L-Proline 0 to 4.5 g/L L-Serine 0 to 3.0 g/L L-Tyrosine 0 to 0.4 g/L Glycine 0 to 7.0 g/L Sodium 20 to 150 mEq/L Potassium 10 to 50 mEq/L Calcium 0 to 15 mEq/L Magnesium 0 to 15 mEq/L Chloride 20 to 150 mEq/L Phosphate 0 to 15 mEq/L Zinc 0 to 100 µmol/L A container for a transparent nutrient infusion preparation comprising a container having a plurality of chambers isolated from each other by partitions capable of being easily opened, wherein one chamber contains a fat emulsion (A) consisting of fat particles having a mean particle size of 0.003 to 0.100 µm and a dispersion medium wherein the fat emulsion contains 0.3 to 15.0 g/dL of fat, 2.5 to 60 g/dL of saccharide and/or a polyhydric sugar alcohol, and an emulsifier selected from the group consisting of egg yolk phospholipid, soybean phospholipid and hydrogenated soybean phospholipid, obtained by finely emulsifying a coarse emulsion of fat using a high pressure spray homogenizer under a pressure of 196130 to 313810 kPa (2000 to 3200 kgf/cm 2 ) with a pass number through said homogenizer of 5 to 30 and the other chamber contains a solution (B) containing electrolytes and/or amino acids. The container for a nutrient infusion preparation according to claim 7, wherein the other chamber contains a solution containing electrolytes and amino acids. The container for a nutrient infusion preparation according to claim 7, wherein the other chambers respectively contain a solution containing electrolytes and a solution containing amino acids.

Inventors: KIKUCHI TAKEO, NAMBA RYOHEI, SATO MAKOTO, YAMASHITA SHUNZO, KIKUCHI, TAKEO,, NAMBA, RYOHEI,, SATO, MAKOTO,, YAMASHITA, SHUNZO,, Kikuchi, Takeo, c/o Nipro Corporation, Namba, Ryohei, c/o Nipro Corporation, Sato, Makoto, c/o Nipro Corporation, Yamashita, Shunzo, c/o Nipro Corporation
Applicants: NIPRO CORP, NIPRO CORPORATION
Application year: 1999
Main classification: A61K9
IPC codes: A61K9